Gilead Says 11% of Prior Non-Responders Cured in Hepatitis Trial

Gilead Sciences Inc. (GILD)’s experimental hepatitis C drug cleared the virus in 11 percent of patients who hadn’t responded to prior treatment, the company said today.

A combination of Gilead’s 7977 drug and the antiviral ribavirin cleared 1 out of 9 so-called “null responder” patients with the most common genotype 1 form of the virus four weeks after ending treatment, the Foster City, California-based company said today in a poster at the European Association for the Study of Liver meeting in Barcelona. The cure rate compares with 88 percent of patients who had never been treated before.

To contact the reporter on this story: Makiko Kitamura in Barcelona via mkitamura1@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.